Advances in Therapy

, Volume 36, Issue 11, pp 3123–3133 | Cite as

Lymph Node Status and Outcomes for Nasopharyngeal Carcinoma According to Histological Subtypes: A SEER Population-Based Retrospective Analysis

  • Rui Guo
  • Han Wu
  • Jun Wang
  • Chen-Lu Lian
  • Zhen-Yu He
  • Wen-Wen Zhang
  • Yong-Xiong ChenEmail author
  • San-Gang WuEmail author
Original Research



We aimed to investigate the clinical effect of histological subtypes on survival in nasopharyngeal carcinoma (NPC), and assess the effect of nodal stage on outcome according to histological subtypes.


Patients with non-metastatic NPC were identified from the Surveillance, Epidemiology and End-Results (SEER) database between 2004 and 2014. Statistical analysis was performed using the chi-squared test, Kaplan–Meier methods, and multivariate Cox regression models.


We identified 2845 patients in this study including 1218 (42.8%), 849 (29.8%), and 778 (27.3%) patients with keratinizing squamous cell carcinoma (KSCC), differentiated non-keratinizing squamous cell carcinoma (DNKSCC), and undifferentiated non-keratinizing squamous cell carcinoma (UNKSCC), respectively. The multivariate analysis indicated that patients with UNKSCC subtype had better NPC-specific survival (NPC-SS) (P < 0.001) compared to KSCC (P < 0.001) and DNKSCC (P < 0.001) patients. The 5-year NPC-SS was 75.2%, 77.9%, and 88.9% in patients with KSCC, DNKSCC, UNKSCC, respectively (P < 0.001). Subgroup analysis showed that advanced nodal stage was related to lower NPC-SS in patients with DNKSCC and UNKSCC but not in patients with KSCC.


Histology is an independent prognostic factor in patients with NPC. However, advanced nodal stage is not associated with lower survival in KSCC.


Keratinizing Lymph node Nasopharyngeal carcinoma Non-keratinizing Undifferentiated 




This work was partly supported by the National Natural Science Foundation of China (no. 81570818). The sponsor also partially funded the journal’s Rapid Service fee.

Editorial Assistance

This paper was proofread by a native English professional with science background at Elixigen Corporation.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.


Rui Guo, Han Wu, Jun Wang, Chen-Lu Lian, Zhen-Yu He, Wen-Wen Zhang, Yong-Xiong Chen, and San-Gang Wu have nothing to disclose.

Compliance with Ethics Guidelines

All SEER data were accessed with approval from the SEER database and, as such, this article does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

The datasets analyzed during the current study are available from the corresponding author on reasonable request.


  1. 1.
    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. Scholar
  2. 2.
    Chan JKC, Bray F, McCarron P, et al. Nasopharyngeal carcinoma. In: Barnes EL, Eveson JW, Reichart P, Sdransky D, editors. Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. Lyon: IARC; 2005. p. 85–97.Google Scholar
  3. 3.
    Yu WM, Hussain SS. Incidence of nasopharyngeal carcinoma in Chinese immigrants, compared with Chinese in China and South East Asia: review. J Laryngol Otol. 2009;123(10):1067–74. Scholar
  4. 4.
    Roy Chattopadhyay N, Das P, Chatterjee K, et al. Higher incidence of nasopharyngeal carcinoma in some regions in the world confers for interplay between genetic factors and external stimuli. Drug Discov Ther. 2017;11(4):170–80. Scholar
  5. 5.
    Ou SH, Zell JA, Ziogas A, Anton-Culver H. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol. 2007;18(1):29–35. Scholar
  6. 6.
    Ruuskanen M, Grenman R, Leivo I, et al. Outcome of nasopharyngeal carcinoma in Finland: a nationwide study. Acta Oncol. 2018;57(2):251–6. Scholar
  7. 7.
    Arnold M, Wildeman MA, Visser O, et al. Lower mortality from nasopharyngeal cancer in the Netherlands since 1970 with differential incidence trends in histopathology. Oral Oncol. 2013;49(3):237–43. Scholar
  8. 8.
    Tang LL, Chen YP, Mao YP, et al. Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era. J Natl Compr Cancer Netw. 2017;15(7):913–9. Scholar
  9. 9.
    Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(4):546–58. Scholar
  10. 10.
    Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61(4):1107–16. Scholar
  11. 11.
    Vazquez A, Khan MN, Govindaraj S, et al. Nasopharyngeal squamous cell carcinoma: a comparative analysis of keratinizing and nonkeratinizing subtypes. Int Forum Allergy Rhinol. 2014;4(8):675–83. Scholar
  12. 12.
    Huang XD, Zhou GQ, Lv JW, et al. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data, intelligence platform-based analysis. Radiother Oncol. 2018;129(2):389–95. Scholar
  13. 13.
    Lee HW, Hwang YH, Han JH, et al. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol. 2010;46(3):209–13. Scholar
  14. 14.
    Cheung F, Chan O, Ng WT, et al. The prognostic value of histological typing in nasopharyngeal carcinoma. Oral Oncol. 2012;48(5):429–33. Scholar
  15. 15.
    Xu C, Chen YP, Liu X, et al. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. Oral Oncol. 2017;69:99–107. Scholar
  16. 16.
    OuYang PY, You KY, Zhang LN, et al. External validity of a prognostic nomogram for locoregionally advanced nasopharyngeal carcinoma based on the 8th edition of the AJCC/UICC staging system: a retrospective cohort study. Cancer Commun (Lond). 2018;38(1):55. Scholar
  17. 17.
    Reddy SP, Raslan WF, Gooneratne S, et al. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol. 1995;16(2):103–8. Scholar
  18. 18.
    Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Incidence—SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2016 Sub (1973–2014 varying)—Linked To County Attributes—Total U.S., 1969–2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2017, based on the November 2016 submission.
  19. 19.
    Hamilton SN, Ho C, Laskin J, et al. Asian versus non-Asian outcomes in nasopharyngeal carcinoma: a North American population-based analysis. Am J Clin Oncol. 2016;39(6):575–80. Scholar
  20. 20.
    Levine PH, Connelly RR, Easton JM. Demographic patterns for nasopharyngeal carcinoma in the United States. Int J Cancer. 1980;26(6):741–8. Scholar
  21. 21.
    Burt RD, Vaughan TL, McKnight B. Descriptive epidemiology and survival analysis of nasopharyngeal carcinoma in the United States. Int J Cancer. 1992;52(4):549–56. Scholar
  22. 22.
    García-Lorenzo J, Farre N, Codina A, et al. Nasopharyngeal carcinoma: 30-year experience of a single institution in a non-endemic area. Clin Transl Oncol. 2017;19(6):777–83. Scholar
  23. 23.
    Petersson F. Nasopharyngeal carcinoma: a review. Semin Diagn Pathol. 2015;32(1):54–73. Scholar
  24. 24.
    Shi W, Pataki I, MacMillan C, et al. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer. 2002;94(7):1997–2006. Scholar
  25. 25.
    Shanmugaratnam K, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer. 1993;71(8):2689–97.;2-h.CrossRefPubMedGoogle Scholar
  26. 26.
    Skinner DW, Van Hasselt CA, Tsao SY. Nasopharyngeal carcinoma: modes of presentation. Ann Otol Rhinol Laryngol. 1991;100(7):544–51. Scholar
  27. 27.
    Amin MB, Edge S, Greene F, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2016.Google Scholar
  28. 28.
    Yang XL, Wang Y, Liang SB, et al. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers. BMC Cancer. 2018;18(1):606. Scholar
  29. 29.
    Lee VH, Lam KO, Chang AT, et al. Management of nasopharyngeal carcinoma: is adjuvant therapy needed? J Oncol Pract. 2018;14(10):594–602. Scholar
  30. 30.
    Ji X, Zhang W, Xie C, et al. Nasopharyngeal carcinoma risk by histologic type in central China: impact of smoking, alcohol and family history. Int J Cancer. 2011;129(3):724–32. Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Radiation OncologySun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer MedicineGuangzhouPeople’s Republic of China
  2. 2.Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Medical CollegeXiamen UniversityXiamenPeople’s Republic of China
  3. 3.Department of Radiation Oncology, Cancer HospitalThe First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical UniversityXiamenPeople’s Republic of China

Personalised recommendations